3410
F. Crestey et al.
PAPER
Anal. Calcd for C16H14N2O3: C, 68.08; H, 5.00; N, 9.92. Found: C,
68.04; H, 5.40; N, 9.52.
1H NMR (CDCl3): d = 1.41–1.51 (m, 8 H), 1.89–1.94 (m, 4 H), 2.98
(t, J = 7.5 Hz, 4 H), 7.97 (d, J = 8.2 Hz, 4 H), 8.24 (d, J = 8.2 Hz,
4 H), 10.06 (s, 2 H).
4-(5-Benzyl-[1,2,4]oxadiazol-3-yl)benzaldehyde (7)
Obtained by method E, starting from 5-benzyl-3-(4-[1,3]-dioxolan-
2-ylphenyl)-[1,2,4]oxadiazole (6; 0.69 g, 2.2 mmol) and PPTS
(0.17 g, 0.7 mmol).
Anal. Calcd for C26H26N4O4: C, 68.11; H, 5.72; N, 12.22. Found: C,
68.10; H, 6.10; N, 12.08.
Acknowledgment
Yield: 0.51 g (88%); beige solid; mp 86 °C; Rf = 0.5 (CH2Cl2).
1H NMR (CDCl3): d = 4.32 (s, 2 H), 7.31–7.39 (m, 5 H), 7.99 (d,
J = 8.4 Hz, 2 H), 8.25 (d, J = 8.4 Hz, 2 H), 10.04 (s, 1 H).
13C NMR (CDCl3): d = 33.1, 127.8, 128.1, 128.9, 129.0, 130.1,
132.2, 133.2, 138.0, 167.7, 178.6, 191.6.
We thank Myriam Segou and Gaëtan Leboucher for their technical
support on the project, Karine Jarsale for the mass spectrometry
measurements and Margareth Lemarié for the elemental analyses.
MS (EI): m/z (%) = 264 (100) [M+], 263 (36), 236 (12), 146 (42),
133 (19), 118 (14), 104 (34), 91 (25), 65 (14).
References
(1) (a) Siméon, F.; Sobrio, F.; Gourand, F.; Barré, L. J. Chem.
Soc., Perkin Trans. 1 2001, 690. (b) Poulain, N.; Dez, I.;
Perrio, C.; Lasne, M.-C.; Prud’homme, M.-P.; Nakache, E.
J. Controlled Release 2003, 92, 27. (c)Grandeury, A.; Petit,
S.; Coste, S.; Coquerel, G.; Perrio, C.; Gouhier, G. Chem.
Commun. 2005, 4007.
(2) Greene, T. W.; Wuts, P. G. M. In Protective Groups in
Organic Synthesis, 3rd ed.; John Wiley and Sons Inc.: New
York, 1999, 312–322.
Anal. Calcd for C16H12N2O2: C, 72.12; H, 4.58; N, 10.60. Found: C,
72.51; H, 4.79; N, 10.13.
a,a¢-Bis[5-(4-formylphenyl)-[1,2,4]oxadiazol-3-yl]-1,3-xylene
(16)
Obtained by method E, starting from a,a¢-bis{5-(4-[1,3]-dioxolan-
2-ylphenyl)-[1,2,4]oxadiazol-3-yl}-1,3-xylene (12; 1.15 g, 2.1
mmol).
(3) Dahnke, K. R.; Paquette, L. A. J. Org. Chem. 1994, 59, 885.
(4) Ouari, O.; Polidori, A.; Pucci, B.; Tordo, P.; Chalier, F. J.
Org. Chem. 1999, 64, 3554.
(5) (a) Eloy, F.; Lenaers, R. Chem. Rev. 1962, 62, 155.
(b) Robertson, G. M. In Comprehensive Organic Functional
Group Transformations, Imines and their N-Substituted
Derivatives: Oximes and their O-R Substituted Analogues,
Vol. 3; Katritzky, A. R.; Meth-Cohn, O.; Rees, C. W., Eds.;
Pergamon: Oxford, 1995, 425–441.
Yield: 0.96 g (100%); orange solid.
1H NMR (CDCl3): d = 4.34 (s, 4 H), 7.36–7.44 (m, 4 H), 7.99 (m,
4 H), 8.25 (m, 4 H), 10.09 (s, 2 H).
MS (EI): m/z (%) = 451 (100) [M + 1], 367 (13), 323 (21), 192 (16),
149 (45), 132 (19).
HRMS (ESI): m/z [M + H]+ calcd for C26H19N4O4: 451.1406; found:
451.1377.
(6) (a) Bell, C. L.; Nambury, C. N. V.; Bauer, L. J. Org. Chem.
1964, 29, 2873. (b) Korbonits, D.; Horvath, K. Heterocycles
1994, 37, 2051. (c) Andersen, K. E.; Lundt, B. F.;
Joergensen, A. S.; Braestrup, C. Eur. J. Med. Chem. 1996,
31, 417. (d) Gangloff, A. R.; Litvak, J.; Shelton, E. J.;
Sperandio, D.; Wang, V. R.; Rice, K. D. Tetrahedron Lett.
2001, 42, 1441.
a,a¢-Bis{5-(4-formylphenyl)-[1,2,4]oxadiazol-3-yl}-1,4-xylene
(17)
Obtained by method F, starting from a,a¢-bis{5-(4-[1,3]-dioxolan-
2-ylphenyl)-[1,2,4]oxadiazol-3-yl}-1,4-xylene (13; 0.44 g, 0.8
mmol) and PPTS (0.12 g, 0.5 mmol).
Yield: 0.35 g (94%); yellow solid.
1H NMR (CDCl3): d = 4.30 (s, 4 H), 7.40 (s, 4 H), 7.98 (d, J = 8.4
Hz, 4 H), 8.24 (d, J = 8.4 Hz, 4 H), 10.08 (s, 2 H).
(7) (a) Palazzo, G.; Strani, G.; Tavella, M. Gazz. Chim. Ital.
1961, 91, 1085. (b) Ooi, N. S.; Wilson, W. S. J. Chem. Soc.,
Perkin Trans. 2 1980, 1792. (c) LaMattina, J. L.; Mularski,
C. J. J. Org. Chem. 1984, 49, 4800. (d) Korbonits, D.;
Kanzel-Svoboda, I.; Gönczi, C.; Simon, K.; Kolonits, P.
Chem. Ber. 1989, 122, 1107. (e) Menzler, S.; Bikker, J. A.;
Horwell, D. C. Tetrahedron Lett. 1998, 39, 7619.
(f) Srivastava, R. M.; Oliveira, F. J. S.; Machado, D. S.;
Souto-Maior, R. M. Synth. Commun. 1999, 29, 1437.
(g) Kayukova, L. A. Pharm. Chem. J. 2005, 39, 539.
(8) Walz, A. J.; Sundberg, R. J. J. Org. Chem. 2000, 65, 8001.
(9) (a) Kawashima, E.; Tabei, K. J. Heterocycl. Chem. 1986, 23,
1657. (b) Payne, R. J.; Daines, A. M.; Clark, B. M.; Abell,
A. D. Bioorg. Med. Chem. 2004, 12, 5785. (c) Montalbetti,
C. A. G. N.; Falque, V. Tetrahedron 2005, 61, 10827.
(d) Shinada, T.; Umezawa, T.; Ando, T.; Kozuma, H.;
Ohfune, Y. Tetrahedron Lett. 2006, 47, 1945. (e) Klutchko,
S. R.; Zhou, H.; Winters, R. T.; Tran, T. P.; Bridges, A. J.;
Althaus, I. W.; Amato, D. M.; Elliott, W. L.; Ellis, P. A.;
Meade, M. A.; Roberts, B. J.; Fry, D. W.; Gonzales, A. J.;
Harvey, P. J.; Nelson, J. M.; Sherwood, V.; Han, H.-K.;
Pace, G.; Smaill, J. B.; Denny, W. A.; Showalter, H. D. H. J.
Med. Chem. 2006, 49, 1475.
MS (EI): m/z (%) = 451 (100) [M + 1], 323 (13), 175 (14), 149 (16).
HRMS (ESI): m/z [M + H]+ calcd for C26H19N4O4: 451.1406; found:
451.1416.
Bis{5-(4-formylphenyl)-[1,2,4]oxadiazol-3-yl}-1,6-hexane (18)
Obtained by method F, starting from bis{5-(4-[1,3]-dioxolan-2-
ylphenyl)-[1,2,4]oxadiazol-3-yl]-1,6-hexane (14; 0.50 g, 1.0
mmol).
Yield: 0.42 g (100%); pale-yellow solid; mp 95 °C.
1H NMR (CDCl3): d = 1.41–1.51 (m, 4 H), 1.89–1.94 (m, 4 H), 2.98
(t, J = 7.5 Hz, 4 H), 7.97 (d, J = 8.2 Hz, 4 H), 8.24 (d, J = 8.2 Hz,
4 H), 10.06 (s, 2 H).
HRMS (ESI): m/z [M + H]+ calcd for C24H23N4O4: 431.1779; found:
451.1702.
Bis{5-(4-formylphenyl)-[1,2,4]oxadiazol-3-yl}-1,8-octane (19)
Obtained by method F, starting from bis{5-(4-[1,3]-dioxolan-2-
ylphenyl)-[1,2,4]oxadiazol-3-yl}-1,8-octane (15; 0.50 g, 1.0
mmol).
(10) Kluger, R.; Shen, L.; Xiao, H.; Jones, R. T. J. Am. Chem.
Yield: 0.42 g (100%); pale-yellow solid; mp 89 °C.
Soc. 1996, 118, 8782.
(11) Inagaki, M.; Matsumoto, S.; Tsuri, T. J. Org. Chem. 2003,
68, 1128.
Synthesis 2007, No. 21, 3406–3410 © Thieme Stuttgart · New York